Towards eradication of hepatitis C virus from dialysis units

The Lancet

Volumn 386, Issue 10003, 2015, Pages 1514-1515

  Jadoul, Michel ^a   Horsmans, Yves ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ELBASVIR; GRAZOPREVIR; PEGINTERFERON; RIBAVIRIN; BENZOFURAN DERIVATIVE; IMIDAZOLE DERIVATIVE; PROTEINASE INHIBITOR; QUINOXALINE DERIVATIVE;

BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER BIOPSY; NOTE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; VIRAL CLEARANCE; VIRUS TRANSMISSION; FEMALE; HEPATITIS C, CHRONIC; MALE; RENAL INSUFFICIENCY, CHRONIC;

BENZOFURANS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; MALE; PROTEASE INHIBITORS; QUINOXALINES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84952705888     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00381-5     Document Type: Note

References (12)

1. RB Fissell, JL Bragg-Gresham, JD Woods et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS Kidney Int 65 2004 2335 2342
2. M Jadoul, F Fabrizi What are the management issues for hepatitis C in dialysis patients?: epidemiology and prevention of hepatitis C virus transmission in the hemodialysis setting Semin Dial 27 2014 449 451
3. DP Webster, P Klenerman, GM Dusheiko Hepatitis C Lancet 385 2015 1124 1135
4. DA Goodkin, B Bieber, B Gillespie, BM Robinson, M Jadoul Hepatitis C infection is very rarely treated among hemodialysis patients Am J Nephrol 38 2013 405 412
5. KDIGO clinical practice guidelines for the prevention, diagnosis, and treatment of hepatitis C in chronic kidney disease Kidney Int Suppl 109 2008 S1 99
6. F Fabrizi, G Dulai, V Dixit, S Bunnapradist, P Martin Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients Aliment Pharmacol Ther 18 2003 1071 1081
7. D Roth, DR Nelson, A Bruchfeld et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study Lancet 2015 published online Oct 6. http://dx.doi.org/10.1016/S0140-6736(15)00349-9
8. M Jadoul, Y Horsmans Impact of liver fibrosis staging in hepatitis C virus (HCV) patients with kidney failure Nephrol Dial Transplant 29 2014 1108 1110
9. RB Fissel, A Karaboyas, BA Bieber et al. Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: finding from the DOPPS Hemodial Int 2015 10.1111/hdi.12315 published online May 14.
10. L Caro, W Marshall, H Feng et al. Coadministration of HCV protease inhibitor grazoprevir with HCV NS5A inhibitor elbasvir has no effect on pravastatin but increases rosuvastatin exposure in healthy subjects Rev Antiviral Ther Infect Dis 4 2015 abstract 17.
11. PY Kwo, MB Badshah New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant setting, drug options in decompensated cirrhosis, and drug options in end-stage renal disease Curr Opin Organ Transplant 20 2015 235 241
12. M Jadoul, JL Poignet, C Geddes et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study Nephrol Dial Transplant 19 2004 904 909